How could Robert F. Kennedy Jr.'s influence affect the Food and Drug Administration?
RFK Jr.'s influence may prompt FDA to grant favors to kratom producers As HHS Secretary, Robert F. Kennedy Jr. used his authority to protect the distribution of Kratom, a substance linked to thousands of deaths. This action led to the Food and Drug Administration granting additional favors to boost kratom. This regulatory shift allowed Kratom mogul Jerry Ross, who benefited from the action, to subsequently pour $162,000 into the defunct RFK Jr. 2024 presidential committee.
- Effect
- Mild negative
- How direct
- Stated in the reporting
- When
- Within weeks
- The story
- Gone quiet
How it reaches Food and Drug Administration
-
Robert F. Kennedy Jr., who serves as U.S. Health and Human Services Secretary, announced initiatives to study rare adverse effects of vaccines and create a dedicated research center. He also discussed the Great American Recovery Initiative, a federal program launched by Donald Trump that provides national resources for addiction and substance abuse disorders. This initiative includes the STREETS program, a $96 million funding effort within SAMHSA.
The full event11independent outlets -
Following Kennedy's action, the Food and Drug Administration granted additional favors to boost kratom, a substance that has been linked to thousands of deaths. This regulatory action benefited Kratom mogul Jerry Ross.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- alternet.org Aug 10
-
government organization in Nonthaburi, Thailand
Everything about Food and Drug Administration
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- RFK Jr. went out of his way to protect the distribution of Kratom, a highly toxic, mind-bending drug, mostly sold in gas stations and convenience marts, that has been linked to thousands of deaths.alternet.org
- RFK Jr. exercised his authority as Health and Human Services secretary in the fall of 2025, calling the governor of Ohio in an effort to stop a state ban on the dangerous substance.alternet.org
- After Food and Drug Administration granted additional favors to boost kratom, Ross wrote another million-dollar check to Kennedy's MAHA PAC.alternet.org
Why it matters
The actions reported suggest a potential conflict of interest where regulatory decisions benefit individuals connected to the administration. By using his executive authority to protect the distribution of a dangerous substance, RFK Jr. enabled a Kratom mogul to profit financially, which then flowed back into Kennedy's political organizations.
This pattern of influence raises questions about the integrity of federal agencies like the Food and Drug Administration. It suggests that policy decisions, such as granting regulatory favors, may be driven by political connections and financial gain rather than public health concerns, undermining the agency's mandate to protect the public.
What we don't know yet
- What specific regulatory changes did the Food and Drug Administration make to boost kratom?
- How many other substances or industries have benefited from similar regulatory favors under the administration?
Is this still moving?
- Reports
- 14
- Developments
- 8
- Repetition
- 64%
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- National Institutes of HealthLikelyNIH may shift research focus toward human-based technologies under new administration
- Centers for Disease Control and PreventionLikelyCDC's operational policies and staffing may be influenced by RFK Jr.'s authority
- CongressPossibleNew federal recovery funding may require Congressional legislative support
Reporting
All 11 outlets- alternet.orgAug 10
- thegazette.comOct 29
- wlec.comOct 23
- manilatimes.netOct 1
- theepochtimes.comSep 21
- rawstory.comAug 17
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.